Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

We are pleased to present Part 6, the final installment of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 6 of this series provides peer-to-peer physician perspectives on the results from the OptiTROP-Breast02 trial.Topics include:Results from OptiTROP-Breast02: Sacituzumab tirumotecan (sac-TMT) as a novel TROP2-directed antibody drug conjugate (ADC)Future direction of ADC treatmentsDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly

We are pleased to present Part 5 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 5 of this series provides peer-to-peer physician perspectives on the results from the TACTIVE-N trial.Topics include:Neoadjuvant vepdegestrant: results of TACTIVE-N trialTolerance in next-generation endocrine therapies: PROTAC estrogen receptor degradersDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly

We are pleased to present Part 4 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial.Topics include:Mechanisms of resistance to CDK4/6 inhibitorsRationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohortDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly

We are pleased to present Part 3 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 3 of this series provides peer-to-peer physician perspectives on strategies for staying on CDK4/6 inhibitor therapy.Topics include:Clinical trial experience managing adverse events of CDK4/6 inhibitors in early breast cancerTreatment persistence during real-world adjuvant CDK4/6 inhibitor therapyDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly

We are pleased to present Part 2 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer.Topics include:Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrenceBalancing efficacy and quality of life during maintenance endocrine therapy with adjuvant CDK4/6 inhibitor treatmentDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly

We are pleased to present Part 1 of an exclusive podcast, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer.Topics include:The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment of early-stage HR-positive/HER2-negative breast cancerLong-term outcomes of CDK4/6 inhibitors including new 7-year data from the monarchE trial and 5-year data from the NATALEE trialDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly